| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Phase 1 data readout example | Phase 1 | — | Subscribe to access the data. | Biologics | Endocrine System | ||
Phase 1 data readout example | Phase 1 | — | Subscribe to access the data. | Biologics | Endocrine System | ||
Phase 1 data readout example | Phase 1 | — | Subscribe to access the data. | Biologics | Endocrine System |
Recent Updates
Recently added Catalysts
iBio, Inc.$1.62
-0.06 (-3.52%)
D 25Pipeline Score Fair Value Pharma · Clinical
Market Cap
91.41 M
EPS
-0.58
P/E Ratio
-
Value Trade
1.30 M
SEC Financials
Q1 2026Dilution Risk
R&D Expenses
3.25 M
Total Assets
85.83 M
Total Liabilities
8.30 M
Equity
77.54 M
D/E Ratio
12,345
19.48 %
Week
-5.15 %
1 Month
-23.33 %
3 Month
84 %
6 Month
-100 %
5 Year
-100 %
All Time
Cash Data
Cash Position
74.82 M
Monthly Burn
2.79 M
Runway
25.1 mo
Burn Trend
StableSEC Filing
May 12, 2026
Overview
Volume
466.96 K
52 Week Range
0.56 - 3.82
% held by Insiders
7.41 %
% held by Institutions
36.94 %
Enterprise Value
18.94 M
Total Shares
34.53 M
Short %
8.16 %
Float Shares
31.53 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for iBio, Inc.
216Total events
3Upcoming
38Tier-1 (high impact)
2010 – 2027Coverage
Upcoming catalysts 3
Event history 213
May 12, 2026
▲IND ClearanceIBIO-600IND
Regulatory clearance to initiate Phase 1 clinical trial of IBIO-600 in Australia
obesitysource ↗
May 12, 2026
▲Preclinical PoCIBIO-610Preclinical
New preclinical data from obese NHP study for IBIO-610: visceral fat reduced by 6.7%, total fat mass by 5.2%
obesitysource ↗
May 12, 2026
▲Pipeline PrioritizationCorporate
Strategic pipeline expansion into pulmonary hypertension associated with heart failure with preserved ejection fraction (PH-HFpEF) with a selective bispecific antibody
PH-HFpEFsource ↗
May 12, 2026
May 12, 2026
▲Runway Guidance UpdateCorporate
Cash runway extended into Q4 fiscal year 2028 via warrant exercises
Apr 8, 2026
▲IND ClearanceIBIO-600IND
Regulatory clearance (CTN acknowledgement from TGA and ethics approval from HREC) to initiate Phase 1 trial of IBIO-600 in Australia
overweight and obese adult participantssource ↗
Q2 2026
▲First Patient DosedIBIO-600Trial
First participant dosing in Phase 1 clinical trial of IBIO-600
obesitysource ↗
Mar 9, 2026
▲Preclinical PoCIBIO-610Preclinical
Preclinical body composition data from obese NHP study showing reduction of 6.7% visceral fat and 5.2% total fat mass
obesitysource ↗
Jan 9, 2026
2026
◆Oral PresentationIBIO-610Presentation
Presentation of complete dataset including additional biomarkers at scientific conferences throughout 2026
obesitysource ↗
Drug Pipeline Intelligence
D25
Pipeline Score $86M
Pipeline ValueFair Value
Valuation Signal1
Drugs Scored0.9x
rNPV / MCap Top 24%
Micro Cap (rank 690 of 906)
Percentile RankiBio, Inc. faces pipeline headwinds (25/100), with $343M risk-adjusted pipeline value, led by IBIO-600 in Overweight , Obesity (Phase 1).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| IBIO-600 Small molecule | Overweight , Obesity | Phase 1 | NCT07487376 | 14% | $343M | RECRUITING | 32 | VERY_FAST | C (55) | May 1, 2027 | - | LOW May 29, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
IBIO-600 | obesity | — | 2025-04-07 | half life: 57-130 days; lean mass increase low dose: 3.1% (163g); lean mass increase high dose: 5.1% (270g) Read More | iBio Announces IBIO-600 Non-Human Primate Data Showing Extended Half-Life and Muscle Growth, and Interim In Vivo Results for First-in-Class Activin E Antibody, Advancing Cardiometabolic and Obesity Pipeline Non-human pri Read More | |
IBIO-600 | obesity | — | 2025-04-07 | half life: 57-130 days; lean mass increase low dose: 3.1% (163g); lean mass increase high dose: 5.1% (270g) Read More | iBio Announces IBIO-600 Non-Human Primate Data Showing Extended Half-Life and Muscle Growth, and Interim In Vivo Results for First-in-Class Activin E Antibody, Advancing Cardiometabolic and Obesity Pipeline Non-human pri Read More | |
IBIO-600 | obesity | — | 2025-04-07 | half life: 57-130 days; lean mass increase low dose: 3.1% (163g); lean mass increase high dose: 5.1% (270g) Read More | iBio Announces IBIO-600 Non-Human Primate Data Showing Extended Half-Life and Muscle Growth, and Interim In Vivo Results for First-in-Class Activin E Antibody, Advancing Cardiometabolic and Obesity Pipeline Non-human pri Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in IBIO
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
IBIO Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
IBIOiBio Reports Q3 Fiscal Year 2026 Financial Results and Provides Corporate Update Received regulatory clearance to initiate its phase 1 clinical trial of IBIO-600 in Australia Announced a strategic pipeline expansion into
iBio, Inc. reported its financial results for the third quarter of fiscal year 2026, highlighting significant advancements including regulatory clearance for the phase 1 clinical trial of IBIO-600. The company's strategic pipeline expansion into treating pulmonary hypertension associated with heart failure has also been noted. However, iBio reported no revenue during this quarter and an increase in R&D expenses, reflecting both challenges and ongoing investments in its product development. Additionally, promising preclinical data for IBIO-610 was announced, showing effective reductions in fat mass in studies with non-human primates.
Read more →IBIOiBio Appoints Distinguished Biotech Leader, Elizabeth Stoner, to its Board of Directors San Diego, California /
iBio appointed Dr. Elizabeth Stoner to its Board of Directors, marking a significant step in the company's transition to a clinical-stage biotech firm. Dr. Stoner brings over 35 years of experience in research and development, having held leadership roles in several biotech companies. Her expertise in clinical strategy is anticipated to be crucial as iBio advances its therapies for obesity and pulmonary hypertension. The CEO expressed optimism about Dr. Stoner's contributions during this pivotal time for the company.
Read more →IBIOiBio Received Regulatory Clearance to Initiate Its Phase 1 Clinical Trial of IBIO-600 in Australia IBIO-600 is a potentially best-in-class, long-acting anti-myostatin monoclonal antibody designed to preserve muscle and i
iBio has received regulatory approval to initiate a Phase 1 clinical trial of IBIO-600, a monoclonal antibody aimed at preserving muscle and improving body composition. The trial will begin dosing participants in the second quarter of 2026, marking a significant milestone for the company as it advances to clinical stages. The study, randomized and placebo-controlled, aims to evaluate safety and pharmacokinetics in overweight and obese adults. Previous studies have shown promising results in terms of muscle preservation and body composition improvements.
Read more →IBIOiBio Reports Preclinical Body Composition Data from Obese Non-Human Primates Treated with IBIO-610, a Potential First-in-Class Treatment for Fat-Selective Weight Loss Study demonstrated reduction of 6.7% visceral fat and
iBio, Inc. has announced promising preclinical data revealing IBIO-610's potential as a first-in-class therapy for fat-selective weight loss in obese non-human primates. The study indicated a 6.7% reduction in visceral fat and a 5.2% reduction in total fat mass, achieved while maintaining lean mass. These findings, supported by previously observed effects in rodents, strengthen the case for IBIO-610's continued development targeting obesity and related diseases. The complete analysis of data will be presented at scientific conferences throughout 2026.
Read more →IBIOiBio Reports Q2 Fiscal Year 2026 Financial Results and Provides Corporate Update Secured $26 Million in PIPE Financing Led by a Top-Tier Biotech Investor to Advance Preclinical Programs and Extend Cash Runway Progressed
iBio, Inc. has reported its Q2 fiscal year 2026 financial results, revealing no revenue but securing $26 million in PIPE financing to enhance its pipeline programs. The funding will aid in the advancement of IBIO-610 and IBIO-600 towards human clinical trials and extends the company's cash runway into fiscal year 2028. Additionally, iBio noted increased research and development costs due to escalating operational expenditures. Despite these challenges, the company continues to make progress with new preclinical data and presentations at industry conferences.
Read more →IBIOiBio Announces $26 Million Private Placement
iBio, Inc. announced a $26 million private placement financing agreement with high-quality institutional investors. The proceeds will help advance its preclinical cardiometabolic programs and support other pipeline assets until 2028. The offering is set to close around January 13, 2026, and involves the sale of over 11 million shares at $2.35 each. While the financing is a positive step for iBio, there are risks associated with the inability to sell unregistered shares and potential market fluctuations.
Read more →IBIOiBio Reports Q1 Fiscal Year 2026 Financial Results and Provides Corporate Update Strengthened cash position and extended runway into the fourth quarter of fiscal year 2027 after closing underwritten public offering with
iBio, Inc. announced its first fiscal quarter 2026 financial results and provided a corporate update, highlighting a robust cash position bolstered by a public offering that could yield up to $100 million in gross proceeds. The presentation of new non-human primate data for the Activin E antibody, IBIO-610, indicates the potential for infrequent dosing while enhancing patient compliance. These developments are part of iBio's ongoing strategy to create next-generation therapies aimed at obesity and cardiometabolic diseases, confirming their commitment to innovation in drug development.
Read more →IBIOiBio Unveils New Non-Human Primate Data on IBIO-610, an Activin E Antibody with Strong Therapeutic Potential for Fat-Selective Weight-Loss and Weight Maintenance Previously reported data showed that in a diet-induced obe
iBio, Inc. has revealed new preclinical data showing the potential of IBIO-610, an Activin E antibody, in fat-selective weight loss and weight maintenance. The study conducted on non-human primates suggests a human half-life of up to 100 days, indicating that treatment could be administered only twice a year. This extended half-life, combined with a unique mechanism of action, positions IBIO-610 as a potential leading therapy for obesity and cardiometabolic diseases, particularly for patients transitioning off GLP-1 therapies.
Read more →IBIOiBio Reports Fiscal Year 2025 Financial Results and Provides Corporate Update San Diego, California /
iBio, Inc. reported its financial results for fiscal year 2025, highlighting a transformative year with advancements in its pipeline for cardiometabolic diseases and obesity. The company showcased promising data for its antibody candidates IBIO-610 and IBIO-600, alongside securing additional funding to support ongoing research. Despite an increase in operating losses and R&D expenditures, iBio's successful transition to Nasdaq and strategic corporate developments position it for growth. Overall, the firm remains focused on delivering transformative therapies while enhancing shareholder value.
Read more →IBIOiBio Announces Proposed Public Offering
iBio, Inc. has announced a proposed public offering that includes pre-funded warrants and Series G and H warrants to purchase its common stock. The proceeds from this offering are intended to support the advancement of its cardiometabolic programs and other pipeline assets. While this decision may enhance iBio's financial position, the completion of the offering is contingent on market conditions and other factors, creating potential risks. The company employs innovative AI-driven approaches in its research and development efforts in biopharmaceuticals.
Read more →IBIOBreakthrough Antibodies for Obesity and Cardiometabolic Diseases Corporate Presentation August 2025 Certain statements in this presentation constitute "forward -looking statements" within the meaning of the Private Secur
iBio is making strides in developing innovative therapies for obesity and cardiometabolic diseases, particularly with its antibodies IBIO-610 and IBIO-600. The company's AI-driven technology aims to optimize the discovery of challenging drug targets, potentially improving weight loss while preserving muscle mass. Key financial highlights indicate sufficient resources for ongoing research, with promising pharmacokinetic data supporting infrequent dosing regimens for its lead product. Overall, iBio’s differentiated approach may position it favorably in the competitive biopharma landscape.
Read more →IBIOBreakthrough Antibodies for Obesity and Cardiometabolic Diseases Corporate Presentation June 2025 Certain statements in this presentation constitute "forward-looking statements" within the meaning of the Private Securiti
iBio's recent corporate presentation highlighted its differentiated pipeline focused on addressing obesity and cardiometabolic diseases through innovative antibody development. The company showcased its AI-driven discovery technology, which aims to expedite the creation of highly developable pre-clinical candidates. Financially, iBio reported $10.5 million in cash, positioning it well for upcoming initiatives. The presentation also underscored its immuno-oncology pipeline, which incorporates advanced mechanisms to improve safety and efficacy.
Read more →IBIOiBio Reports Fiscal Third Quarter 2025 Financial Results
iBio, Inc. reported its financial results for Q3 2025, highlighting significant progress in its pipeline and a recent $6.2 million equity raise following its move to Nasdaq. The company expressed optimism about the potential of IBIO-600 and a newly in-licensed Activin E antibody to address cardiometabolic diseases and obesity. However, they caution that forward-looking statements may not come to fruition due to various risks, including the timeline for regulatory submissions.
Read more →IBIOiBio Expands Cardiometabolic and Obesity Pipeline through Licensing of First-in-Class Antibody Targeting Activin E from AstralBio In-Licensing of novel activin E antibody underscores iBio's commitment to delivering meani
iBio has announced a licensing agreement with AstralBio for a first-in-class antibody targeting Activin E, aimed at treating obesity and cardiometabolic diseases. This antibody is expected to induce fat-selective weight loss and improve overall health in affected individuals. Preclinical studies have shown promising results, and iBio plans to advance testing in more complex models. Additionally, the collaboration includes the development of a fifth target for cardiometabolic disease, presenting further opportunities for advancements in this area.
Read more →IBIOBreakthrough Antibodies for Obesity and Cardiometabolic Diseases Enabled by an AI-Platform Scalable for Future High-Value Indications Corporate Presentation April 2025 Certain statements in this presentation constitute "
The article discusses iBio's innovative approach to developing antibodies for obesity and cardiometabolic diseases enabled by an AI platform. The presentation highlights recent clinical milestones, demonstrating the effectiveness of their unique antibody mechanisms, which may reduce toxicity while selectively targeting cancer cells. The integration of technology in the discovery process may present a more efficient pathway for therapeutic development. However, the complexity of these advancements poses challenges in stakeholder comprehension and potential market entry timelines.
Read more →IBIOiBio Announces IBIO-600 Non-Human Primate Data Showing Extended Half-Life and Muscle Growth, and Interim In Vivo Results for First-in-Class Activin E Antibody, Advancing Cardiometabolic and Obesity Pipeline Non-human pri
iBio, Inc. announced encouraging findings related to IBIO-600, a novel long-acting anti-myostatin antibody, showcasing an extended potential half-life of up to 130 days based on non-human primate studies. The results indicated dose-dependent increases in lean mass and reductions in fat mass. Additionally, iBio shared interim data on a first-in-class Activin E antibody, highlighting its capability to promote substantial weight loss when combined with a GLP-1 receptor agonist. iBio is on track for a regulatory submission of IBIO-600 by Q1 2026.
Read more →IBIOiBio to Begin Trading on the Nasdaq Stock Exchange
iBio, Inc. has announced that its common stock has been approved for listing on the Nasdaq Capital Market, transitioning from the NYSE American. The company shares are set to begin trading on Nasdaq on March 4, 2025, while still trading on NYSE American until March 3, 2025. CEO Martin Brenner expressed optimism that this move will enhance the visibility and liquidity of iBio's shares and increase exposure to institutional investors.
Read more →IBIOiBio Reports Fiscal Second Quarter 2025 Financial Results
iBio, Inc. has reported its financial results for the second quarter of fiscal 2025, highlighting advancements in their preclinical pipeline, including the in-licensing of IBIO-600 and the initiation of a bispecific antibody program. CEO Dr. Martin Brenner emphasized the company's commitment to innovation and improving treatments for cardiometabolic diseases and obesity. The report also includes forward-looking statements regarding their potential future progress and risks involved in achieving their objectives.
Read more →IBIOiBio Announces New Investments from Board Members and Officers
iBio, Inc. has announced a successful private placement offering worth over $650,000, primarily from its Board of Directors and Officers, demonstrating their support for the company's strategies. The funds will aid iBio's focus on developing novel therapeutics aimed at addressing cardiometabolic diseases and obesity. CEO Martin Brenner emphasized the company's commitment to creating innovative antibody treatments that promote healthy weight loss while retaining muscle mass. However, the announcement included forward-looking statements that caution potential investors about various risks inherent in the biotech industry, including regulatory approvals and market acceptance.
Read more →IBIOBreakthrough Antibodies for Obesity and Cardiometabolic Diseases Enabled by an AI-Platform Scalable for Future High-Value Indications Corporate Presentation January 2025 Certain statements in this presentation constitute
iBio has presented its advancement in antibodies targeting EGFRvIII, a variant linked to several cancers, through an AI-driven platform. This includes a notable focus on high-antibody-dependent cellular cytotoxicity (ADCC) mechanisms, promising reduced toxicity and expanded therapeutic options. Their approach specifically spares healthy cells while effectively attacking cancerous ones. The presentation underlines the company’s strategic collaborations and the positive outlook for future clinical applications.
Read more →IBIOiBio Expands Cardiometabolic and Obesity Program with Anti-Myostatin Antibody Discovered Using its Proprietary Platform, In-Licensed from AstralBio Building on the success of the anti-Myostatin program, iBio Launches New
iBio, Inc. has announced an expansion of its cardiometabolic and obesity treatment program by in-licensing a new anti-myostatin antibody, IBIO-600, from AstralBio. This antibody is expected to promote weight loss and prevent muscle loss while allowing for less frequent dosing than current obesity treatments. The company also initiated a bispecific antibody program targeting myostatin/activin A to treat obesity and related disorders, planning clinical investigations in 2026. The collaboration with AstralBio aims to leverage advanced technologies for rapid drug development.
Read more →IBIOiBio Strengthens Board with Appointment of Two New Independent Directors
iBio, Inc. has appointed David Arkowitz and Antonio Parada as independent directors to strengthen its board. Both individuals bring significant experience in the biotech sector, with Arkowitz's financial expertise and Parada's background in antibody discovery being particularly beneficial for iBio's development goals. This strategic move aligns with iBio's vision of advancing its clinical pipeline focused on therapeutic antibodies for cardiometabolic diseases and oncology. The company aims to leverage the unique skills of its new directors to overcome challenges in drug discovery and expedite its growth strategy.
Read more →IBIOiBio Reports Fiscal First Quarter 202 5 Financial Results Advanced myostatin program with dosing underway in non-human primate study
iBio, Inc. reported its financial results for the fiscal first quarter of 2025 and announced advancements in its myostatin program, which includes dosing in non-human primate studies. The company is collaborating with AstralBio to develop a lead molecule targeting muscle wasting and obesity. iBio also noted the strengthening of its leadership team with the hiring of a new business development executive. The company expressed optimism about its progress and plans to share further data in the upcoming months as it continues to build its pipeline in cardiometabolic diseases.
Read more →IBIOOctober 2024 Tomorrow's Precision Antibody Therapeutics Powered by Machine Learning 2 Forward-looking Statements Certain statements in this presentation constitute "forward-looking statements" within the meaning of the P
iBio is advancing its development of precision antibody therapeutics targeting EGFRvIII, which is implicated in several cancers. Their proprietary antibodies demonstrate selective binding to tumor cells without affecting healthy tissue, reducing the risk of toxicity. Recent milestones, including substantial partnerships with notable firms, suggest a promising outlook for iBio's innovative therapies in cancer treatment. Preclinical results indicate effective tumor inhibition and regression, marking progress toward future clinical applications.
Read more →IBIOiBio Reports Fiscal Year 2024 Financial Results and Provides Corporate Update San Diego, California /
iBio, Inc. announced its fiscal year 2024 financial results, highlighting a 100% revenue increase compared to the previous year. The company improved its financial standing by eliminating debts and obtaining non-dilutive funding. Despite these advancements, iBio reported a consolidated net loss of $24.9 million, raising concerns regarding its ability to continue operations without additional capital. Management expressed optimism about pursuing future projects and advancing their drug discovery platform.
Read more →IBIOiBio Closes Sale of Manufacturing Facility in Texas - The sale of the facility eliminates $13.2M of secured debt secured - - Completes iBio's transition to an AI and precision biologics innovation company
iBio has successfully closed the sale of its manufacturing facility in Bryan, Texas to the Texas A&M University System for $8.5 million. This transaction eliminates approximately $13.2 million in secured debt, marking a crucial step in iBio's transition to an AI and precision biologics innovation company. The company plans to use the freed-up capital to expand into new therapeutic areas and strengthen its research and development efforts from its new headquarters in San Diego.
Read more →IBIOJune 2024 Tomorrow's Precision Antibody Therapeutics Powered by Machine Learning 2 Forward-looking Statements Certain statements in this presentation constitute "forward-looking statements" within the meaning of the Priv
iBio is advancing its therapeutics targeting EGFRvIII-related cancers, including glioblastoma and non-small cell lung cancer, using machine learning to enhance antibody efficacy. Recent preclinical tests have demonstrated that iBio's EGFRvIII-specific antibodies can selectively kill cancerous cells without affecting healthy tissue, indicating a potential reduction in toxicity. Additionally, the introduction of bispecific antibodies targeting Trop-2 offers expanded therapeutic opportunities, further positioning iBio within the competitive landscape of immunotherapy. Significant financial transactions and partnerships highlight the growing interest in developing these innovative cancer therapies.
Read more →IBIOiBio Reports Fiscal Third Quarter 2024 Financial Results and Provides Corporate Update Strengthened cash position with investment by healthcare specialist investors Expanding into cardio-metabolic space through AstralBio
iBio, Inc. reported its fiscal third quarter 2024 financial results, highlighting a strengthened cash position following new investments. The company is expanding its focus into the cardio-metabolic space through a collaboration with AstralBio aimed at developing novel antibody treatments for obesity and muscle wasting. CEO Dr. Martin Brenner noted that this partnership allows them to accelerate their research and diversify their pipeline. iBio is positioning itself to advance its internal projects in both immuno-oncology and cardiometabolism.
Read more →IBIOiBio Announces $15.0 Million Private Placement - Purchase price of $2.85 represents a premium of 148+% to last close - BRYAN, Texas and
iBio, Inc. has announced a $15 million private placement financing, priced at $2.85 per share, reflecting a significant premium over its last closing price. The offering attracted notable participation from several institutional investors and aims to support the company's operations and research through fiscal 2025. The securities involved are unregistered, which presents market limitations for investors. The company expressed optimism regarding the innovative potential of their AI-driven antibody treatments.
Read more →IBIOiBio Announces Sale of Preclinical PD-1 Agonist Antibody Program to Otsuka - Deal includes $1 million upfront and potential future milestone payments - - iBio's proprietary therapeutic pipeline will now be comprised enti
iBio, Inc. has entered into an asset purchase agreement with Otsuka Pharmaceutical Co., Ltd., selling its preclinical PD-1 agonist antibody program. The deal includes an upfront payment of $1 million and the potential for additional milestone payments that could total up to $52.5 million. This sale enables iBio to concentrate on its immuno-oncology candidates while providing Otsuka with the opportunity to further develop the PD-1 agonist program.
Read more →IBIOJanuary 2024 Tomorrow's Precision Antibody Therapeutics Powered by Machine Learning 2 Forward-looking Statements Certain statements in this presentation constitute "forward-looking statements" within the meaning of the P
The article discusses the advancements of iBio in developing antibody therapeutics, particularly focusing on their selective EGFRvIII-specific monoclonal antibodies, which demonstrate effectiveness against tumor cells while sparing healthy cells. Additionally, iBio's approach to PD-1 agonism is highlighted as a potential strategy for treating inflammatory diseases. These developments reflect a growing confidence in immune-oncology and inflammatory disease therapies, bolstered by recent partnerships and milestones in the industry.
Read more →IBIOiBio Amends and Extends Maturity of Credit Agreement - Extends maturity date to
iBio, Inc. has announced an amendment to its Credit Agreement with Woodforest National Bank, extending the maturity date to March 29, 2024. This extension provides additional financial flexibility for iBio as it works on the planned sale of its legacy CDMO business. The company also aims to advance its AI-driven drug discovery platform and immunotherapy pipeline during this period. The decision is viewed as a strategic move to ensure continued operational progress.
Read more →IBIOiBio, Inc. Announces Pricing of $4.5 Million Public Offering BRYAN, Texas and
iBio, Inc. has announced the pricing of its public offering of 2,250,000 shares of common stock, priced at $2.00 per share, aiming to raise approximately $4.5 million. The proceeds from this offering will primarily support working capital, including research and development activities, and may also fund retention payments to employees. The offering is set to close around December 7, 2023, pending customary conditions.
Read more →IBIOiBio Announces Reverse Stock Split BRYAN, Texas and
iBio, Inc. has announced a 20-to-1 reverse stock split, effective November 29, 2023. This decision was approved by stockholders at the 2023 Annual Meeting, aiming to consolidate the company's shares from over 28 million to about 1.4 million. While the stockholder ownership percentages will be intact, those with fractional shares will receive cash payments. The company hopes this action will enhance trading efficiency and align with its mission to innovate in biopharmaceuticals.
Read more →IBIOOctober 2023 AI-Powered Precision Antibody Therapeutics 2 Forward-looking Statements Certain statements in this presentation constitute "forward-looking statements" within the meaning of the Private Securities Litigation
The article discusses iBio's advancements in AI-powered precision antibody therapeutics, focusing on their novel approaches to targeting cancer through mechanisms such as PD-1 agonism and the development of bi-specific antibodies. Several candidates are positioned for various oncological applications, including the targeting of Trop-2 overexpressed cancer cells. iBio's progress is highlighted through recent acquired transactions by larger firms, indicating a growing interest in their therapeutic innovations. The article emphasizes the potential benefits of iBio's therapies while indicating the ongoing exploration in their efficacy and safety profiles.
Read more →IBIOiBio Announces Filing of 2023 Annual Report on SEC Form 10-K BRYAN, Texas and SAN DIEGO, California / September 27 , 2023 / (GLOBE NEWSWIRE) / iBio, Inc. (NYSEA:IBIO) ("iBio" or the "Company"), an AI-driven innovator of
iBio, Inc. announced the filing of its annual report on Form 10-K for the fiscal year ending June 30, 2023, revealing significant financial losses. The company reported no revenues and a net loss of $65 million, an increase from the previous year. Additionally, an audit opinion expressed concerns regarding the company's ability to continue operations. iBio is in the process of selling a key manufacturing facility to improve its financial situation and extend its operational runway.
Read more →IBIOPRO FORMA CONDENSED CONSOLIDATED FINANCIAL STATEMENTS OF IBIO, INC. (UNAUDITED) On
iBio, Inc. has announced the sale of its cGMP biologics manufacturing facility in Texas for $17.25 million, which aims to provide essential non-dilutive funding. This divestiture enables the company to concentrate on advancing its AI drug discovery platform and immunotherapy pipeline in California. The move is part of a broader effort to realign its business strategy, although the latest pro forma financial statements indicate substantial losses, particularly from discontinued operations.
Read more →IBIOJuly 2023 AI-Powered Precision Antibody Therapeutics 2 Forward-looking Statements Certain statements in this presentation constitute "forward-looking statements" within the meaning of the Private Securities Litigation Re
iBio presented advanced findings related to its antibody therapeutics focused on PD-1 agonism. The data suggests potential efficacy in treating inflammatory diseases by selectively agonizing PD-1 without antagonizing the PD-1:PD-L1 interaction. iBio's candidates demonstrated superior performance compared to benchmark antibodies in preclinical assessments. The presentation emphasized the significance of these therapies for conditions such as rheumatoid arthritis and cancer-related diseases, with recent positive results from Eli Lilly indicating progress in the field.
Read more →IBIOiBio Appoints Dr. Martin Brenner as CEO, Felipe Duran as CFO to Oversee Company's Next Stage of Growth - Board appointments solidify management team to lead iBio's AI-powered biotech strategy - BRYAN, Texas and SAN DIEGO
iBio has appointed Dr. Martin Brenner as CEO and Felipe Duran as CFO to lead the company in its growth phase, following their interim leadership roles since early 2023. The board's decision reflects confidence in their capabilities to advance iBio's AI-powered biotech strategy, which includes developing bispecific immuno-oncology therapies. Dr. Brenner has a strong background in drug discovery, while Mr. Duran has experience in financial planning and analysis from his previous roles in the pharmaceutical sector. This solid management team is poised to enhance iBio's operations and strategic direction.
Read more →IBIOApril 2023 Forward-looking Statements Certain statements in this presentation constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Words such as
iBio, Inc. has detailed its forward-looking statements for April 2023, highlighting a robust pipeline that includes 10 preclinical immuno-oncology biologics. The company is advancing its lead asset, IBIO-101, which is an anti-CD25 biologic currently in development. In addition, iBio's use of AI-driven discovery technologies is expected to bolster the effectiveness and variety of its biologic candidates. Financially, as of December 31, 2022, iBio reported a cash balance of $9.9 million and reduced operational expenditures.
Read more →IBIOiBio Announces Closing of $3.5 Million Underwritten Public Offering
iBio Announces Closing of $3.5 Million Underwritten Public Offering BRYAN, Texas, Dec. 9, 2022 (GLOBE NEWSWIRE) - iBio, Inc. (NYSEA: IBIO) ("iBio" or the "Company"), an AI-driven innovator of precision antibody immunotherapies, today announced the closing of its previously annou
Read more →IBIOiBio Announces Proposed Underwritten Public Offering
iBio Announces Proposed Underwritten Public Offering BRYAN, Texas, Dec. 6, 2022 (GLOBE NEWSWIRE) - iBio, Inc. (NYSEA: IBIO) ("iBio" or the "Company"), an AI-driven innovator of precision antibody immunotherapies, today announced it intends to offer and sell, subject to market an
Read more →IBIOiBio Announces CEO Departure BRYAN, Texas /
iBio Announces CEO Departure BRYAN, Texas / December 2, 2022 / (GLOBE NEWSWIRE/ iBio, Inc. (NYSEA:IBIO) ("iBio" or the "Company"), an AI-driven innovator of precision antibody immunotherapies, today announced the Board of Directors (the "Board") and Thomas F. Isett, the Company'
Read more →IBIOiBio Accelerates Transformation to AI-Powered Biotech - Divesting CDMO business and cGMP biologics manufacturing facility - - Investing in pipeline of immuno-oncology assets and AI-based drug discovery platform - - Restr
iBio Accelerates Transformation to AI-Powered Biotech - Divesting CDMO business and cGMP biologics manufacturing facility - - Investing in pipeline of immuno-oncology assets and AI-based drug discovery platform - - Restructuring measures to result in ~50% annualized cost savin
Read more →IBIONovember 2022 © iBio, Inc., All Right Reserved Forward-looking statements Certain statements in this presentation constitute "forward-looking statements" within the meaning of the Private Securities Litigation Refor
CSO Robert Lutz, MBA CFBO Marc Banjak GC Lisa Middlebrook CHRO Tom Isett CEO iBio: Summary Pipeline of difficult to find biologics - Pipeline of 10 preclinical primarily immuno- oncology (I/O) biologics - Targets have been of interest to major I/O companies - Lead asset is a next
Read more →IBIOGrowingTomorrow's Biologics CORPORATE PRESENTATION October 2022 Tom Isett, Chairman & CEO 2022 iBio, Inc. All Rights Reserved. 2 Forward-Looking Statements Certain statements in this presentation constitute forward-looki
Fraunhofer USA for $28M in May 2021 10732More (25 U.S.)(9 U.S.)progressing to filing 23 iBio: Leveraging Capabilities Combing platforms to create a biotech company with its own end-to-end discovery capabilities Pipeline of promising immunotherapy candidates, with a focus on immun
Read more →IBIOiBio Reports Preliminary Unaudited Fiscal Year 2022 Financial Results and Provides Corporate Update Bryan, Texas and San Diego, California /
iBio Reports Preliminary Unaudited Fiscal Year 2022 Financial Results and Provides Corporate Update Bryan, Texas and San Diego, California / September 27, 2022 / (GLOBE NEWSWIRE) / iBio, Inc. (NYSEA:IBIO) ("iBio" or the "Company"), a developer of next-generation biopharmaceutica
Read more →IBIOiBio Acquires RubrYc Therapeutics' AI Drug Discovery Platform and Pipeline - Positions Company for leadership in AI-powered drug discovery - - Expands iBio's immuno-oncology pipeline with three new candidates - - Hosting
iBio Acquires RubrYc Therapeutics' AI Drug Discovery Platform and Pipeline - Positions Company for leadership in AI-powered drug discovery - - Expands iBio's immuno-oncology pipeline with three new candidates - - Hosting investor call on September 27th to discuss transaction,
Read more →IBIOiBio Provides Update on Development of Next-Gen COVID-19 Vaccine Candidate - Manufactured first batch of drug substance under cGMP conditions - - Analysis of challenge study data underway - Bryan, Texas /
iBio Provides Update on Development of Next-Gen COVID-19 Vaccine Candidate - Manufactured first batch of drug substance under cGMP conditions - - Analysis of challenge study data underway - Bryan, Texas / August 16, 2022 / (GLOBE NEWSWIRE) / iBio, Inc. (NYSEA:IBIO) ("iBio" or
Read more →IBIOGrowing Tomorrow's Biologics CORPORATE PRESENTATION May 2022 Tom Isett, Chairman & CEO 2022 iBio, Inc. All Rights Reserved. 2 Forward-Looking Statements Certain statements in this presentation constitute forward-looking
Fraunhofer USA for $28M in May 2021 28 Financial Overview Publicly traded (NYSEA: IBIO) since Jan 2008 Approximately $48.6M in cash and cash equivalents plus investments in debt securities, excluding $5.9M of restricted cash (31 Mar 2022) Approximately 218.2M common shares & 17.1
Read more →IBIOiBio Reports Fiscal Third Quarter 2022 Financial Results and Provides Corporate Update Bryan, Texas /
iBio Reports Fiscal Third Quarter 2022 Financial Results and Provides Corporate Update Bryan, Texas / May 12, 2022 / (GLOBE NEWSWIRE) / iBio, Inc. (NYSEA:IBIO) ("iBio" or the "Company"), a developer of next-generation biopharmaceuticals and pioneer of the sustainable FastPharmin
Read more →IBIOGrowing Tomorrow's Biologics CORPORATE PRESENTATION March 2022 Tom Isett, Chairman & CEO © 2022 iBio , Inc. All Rights Reserved. 2 Forward - Looking Statements Certain statements in this presentation constitute "for
Dec 2022) Discovery Announce lead for 1 program 2 - 4 leads and targets announced Animal Health Program Next Milestone Subsequent Key Milestone FastPharming Comparability v. Mammalian for IBIO - 101 Validating 3 rd Party Contracts CDMO Services 30 iBio : Leveraging Capabilities t
Read more →IBIOiBio Reports Fiscal Second Quarter 2022 Financial Results and Provides Corporate Update Bryan, Texas /
Reports Fiscal Second Quarter 2022 Financial Results and Provides Corporate Update Texas / February 14, 2022 / (GLOBE NEWSWIRE) / iBio, Inc. (NYSEA:IBIO) ("iBio" or the "Company"), a developer of next-generation biopharmaceuticals and pioneer of the sustainable FastPharming Ma
Read more →IBIOiBio Announces Progression of Vaccine Program for Multi-Variant COVID-19 Disease - IBIO-202 Designed to Address Unmet Needs for Durability, Access, and Variant-inclusion - Bryan, Texas /
iBio Announces Progression of Vaccine Program for Multi-Variant COVID-19 Disease - IBIO-202 Designed to Address Unmet Needs for Durability, Access, and Variant-inclusion - Bryan, Texas / January 26, 2022 / (GLOBE NEWSWIRE) / iBio, Inc. (NYSEA:IBIO) ("iBio" or the "Company"), a
Read more →IBIOiBio Announces Partial Adjournment of Annual Meeting of Shareholders to
Announces Partial Adjournment of Annual Meeting of Shareholders to January 31, 2022 Continue to Support Reverse Split and Authorized Share Proposals by a 2-to-1 Margin - Bryan, Texas / December 22, 2021 / (GLOBE NEWSWIRE) / iBio, Inc. (NYSEA:IBIO) ("iBio" or the "Company"), a
Read more →IBIOiBio Announces Partial Adjournment of Annual Meeting to December 22 - Shareholders Presently Supporting Reverse Split and Authorized Share Proposals by a 2-to-1 Margin - Bryan, Texas /
iBio Announces Partial Adjournment of Annual Meeting to December 22 - Shareholders Presently Supporting Reverse Split and Authorized Share Proposals by a 2-to-1 Margin - Bryan, Texas / December 10, 2021 / (GLOBE NEWSWIRE) / iBio, Inc. (NYSEA:IBIO) ("iBio" or the "Company"), a d
Read more →IBIOiBio Reports Fiscal First Quarter 2022 Financial Results and Provides Corporate Update - Adds First New Anti-cancer Target for Development in Partnership with RubrYc Therapeutics - - Initiates Research Collaboration with
iBio Reports Fiscal First Quarter 2022 Financial Results and Provides Corporate Update - Adds First New Anti-cancer Target for Development in Partnership with RubrYc Therapeutics - - Initiates Research Collaboration with UT Southwestern to Study Anti-fibrotics in Oncology - -
Read more →IBIOiBio Acquires FastPharming Manufacturing Facility - Takes Sole Ownership of CDMO Subsidiary & U.S. Manufacturing Rights - - Reduces Carrying Costs by Approximately 67%
iBio Acquires FastPharming Manufacturing - Takes Sole Ownership of CDMO Subsidiary & U.S. Manufacturing Rights - - Reduces Carrying Costs by Approximately 67% Nov. 3, 2021 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) ("iBio" or the "Company"), a developer of next-generation b
Read more →IBIOiBio Reports Fourth Quarter and Fiscal Year 2021 Financial Results and Provides Corporate Update Expanded Immuno-Oncology Pipeline with License of Next-Gen anti-CD25 Antibody for Solid Tumors Paired Access to RubrYc's An
iBio Reports Fourth Quarter and Fiscal Year 2021 Financial Results and Provides Corporate Update Expanded Immuno-Oncology Pipeline with License of Next-Gen anti-CD25 Antibody for Solid Tumors Paired Access to RubrYc's Antibody Discovery Platform with FastPharming and Glycaneeri
Read more →IBIOGrowing A Next - Gen Biologics Pipeline CORPORATE PRESENTATION: August 2021 Tom Isett, Chairman & CEO Certain statements in this presentation constitute "forward - looking statements" within the meaning of the Private Se
Growing A Next - Gen Biologics Pipeline CORPORATE PRESENTATION: August 2021 Tom Isett, Chairman & CEO Certain statements in this presentation constitute "forward - looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 , as amended . Words
Read more →IBIOTHIRD AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF RUBRYC THERAPEUTICS, INC. (Pursuant to Sections 242 and 245 of the General Corporation Law of the State of Delaware) RubrYc Therapeutics, Inc., a corporation org
THIRD AMENDED AND RESTATED CERTIFICATE OF INCORPORATION RUBRYC THERAPEUTICS, INC. (Pursuant to Sections 242 and 245 of the General Corporation Law of the State of Delaware) RubrYc Therapeutics, Inc., a corporation organized and existing under and by virtue of the provisions
Read more →IBIOiBio Appoints William D. Clark to its Board of Directors - Industry veteran adds deep expertise in immuno-oncology to the Board - Bryan, Texas /
Appoints William D. Clark to its Board of Directors - Industry veteran adds deep expertise in immuno-oncology to the Board - Texas / August 26, 2021 / (GLOBE NEWSWIRE) / iBio, Inc. (NYSEA:IBIO) ("iBio" or the "Company"), a developer of next-generation biopharmaceuticals and p
Read more →IBIOiBio Reports Successful Preclinical Immunization Studies with Next-Gen Nucleocapsid COVID-19 Vaccine Candidate Bryan, TX /
iBio Reports Successful Preclinical Immunization Studies with Next-Gen Nucleocapsid COVID-19 Vaccine Candidate Bryan, TX / July 15, 2021 / (GLOBE NEWSWIRE) / iBio, Inc. (NYSEA:IBIO) ("iBio" or the "Company"), a biotech innovator and biologics contract manufacturing organizati
Read more →IBIOiBio Further Strengthens Board with Appointment of Veteran Biopharmaceutical Executive, Eef Schimmelpennink Bryan, Texas /
Further Strengthens Board with Appointment of Veteran Biopharmaceutical Executive, Eef Schimmelpennink Texas / June 9, 2021 / (GLOBE NEWSWIRE) / iBio, Inc. (NYSEA:IBIO) ("iBio" or the "Company"), a biotech innovator and biologics contract manufacturing organization, announced t
Read more →IBIOiBio Reports Fiscal Third Quarter 2021 Financial Results and Provides Corporate Update Bryan, TX /
iBio Reports Fiscal Third Quarter 2021 Financial Results and Provides Corporate Update Bryan, TX / May 17, 2021 / (GLOBE NEWSWIRE) / iBio, Inc. (NYSEA:IBIO) ("iBio" or the "Company"), a biotech innovator and biologics contract manufacturing organization, today announced its f
Read more →IBIOiBio Reports Successful COVID-19 Vaccine Toxicology Study Results and Announces Next-Gen COVID-19 Vaccine Program Bryan, TX /
iBio Reports Successful COVID-19 Vaccine Toxicology Study Results and Announces Next-Gen COVID-19 Vaccine Program Bryan, TX / May 6, 2021 / (GLOBE NEWSWIRE) / iBio, Inc. (NYSEA:IBIO) ("iBio" or the "Company"), a biotech innovator and biologics contract manufacturing organizati
Read more →IBIOiBio Reports Fiscal Second Quarter 2021 Financial Results and Provides Corporate Update Bryan, TX /
Fiscal Second Quarter 2021 Financial Results and Provides Corporate Update / February 16, 2021 / (GLOBE NEWSWIRE) / iBio, Inc. (NYSEA:IBIO) ("iBio" or the "Company"), a biotech innovator and biologics contract manufacturing organization, today announced its financial results fo
Read more →IBIOiBio Appoints Robert M. Lutz as Chief Financial & Business Officer BRYAN, Texas /
Appoints Robert M. Lutz as Chief Financial & Business Officer Texas / February 16, 2021 / (GLOBE NEWSWIRE) / iBio, Inc. (NYSEA:IBIO) ("iBio" or the "Company"), a biotech innovator and biologics contract manufacturing organization, today announced the appointment of Robert M. Lu
Read more →IBIOiBio Appoints Dr. Martin B. Brenner as Chief Scientific Officer Bryan, Texas /
Appoints Dr. Martin B. Brenner as Chief Scientific Officer Texas / December 28, 2020 / (GLOBE NEWSWIRE) / iBio, Inc. (NYSEA:IBIO) ("iBio" or the "Company"), a biotech innovator and biologics contract manufacturing organization, today announced the appointment of Martin B. Brenn
Read more →IBIOiBio Announces Closing of its Public Offering of Common Stock Bryan, Texas /
Announces Closing of its Public Offering of Common Stock Texas / December 10, 2020 / (GLOBE NEWSWIRE) / iBio, Inc. (NYSEA:IBIO) ("iBio" or the "Company"), a biotech innovator and biologics contract manufacturing organization, today announced the closing of its underwritten publ
Read more →IBIOiBio Announces Proposed Public Offering of Common Stock Bryan, Texas /
Announces Proposed Public Offering of Common Stock Texas / December 7, 2020 / (GLOBE NEWSWIRE) / iBio, Inc. (NYSEA:IBIO) ("iBio" or the "Company"), a biotech innovator and biologics contract manufacturing organization, today announced an underwritten public offering of its com
Read more →IBIOiBio Reports Fiscal First Quarter 2021 Financial Results and Provides Corporate Update Bryan, TX /
iBio Reports Fiscal First Quarter 2021 Financial Results and Provides Corporate Update Bryan, TX / November 16, 2020 / (GLOBE NEWSWIRE) / iBio, Inc. (NYSEA:IBIO) ("iBio" or the "Company"), a biotech innovator and biologics contract manufacturing organization, today announced
Read more →IBIOiBio Announces Appointment of Randy J. Maddux as Chief Operating Officer - Brings 20 Years of Global Biotech Operations and Business Development Experience - BRYAN, Texas /
iBio Announces Appointment of Randy J. Maddux as Chief Operating Officer - Brings >20 Years of Global Biotech Operations and Business Development Experience - BRYAN, Texas / November 3, 2020 / (GLOBE NEWSWIRE) / iBio, Inc. (NYSEA:IBIO) ("iBio" or the "Company"), a biotech in
Read more →IBIOiBio Announces Appointment of Dr. Linda Armstrong to Board of Directors - Accomplished Biopharm Exec with Years of Clinical Experience in Respiratory Diseases - - To be Appointed to the Board's New Science & Technology C
iBio Announces Appointment of Dr. Linda Armstrong to Board of Directors - Accomplished Biopharm Exec with Years of Clinical Experience in Respiratory Diseases - - To be Appointed to the Board's New Science & Technology Committee - BRYAN, Texas / October 14, 2020 / (GLOBE N
Read more →IBIOiBio Announces Financial Results for Fiscal Year Ended
iBio Announces Financial Results for Fiscal Year Ended June 30, 2020 Bryan, TX / October13, 2020 / (GLOBE NEWSWIRE) / iBio, Inc. (NYSEA:IBIO) ("iBio" or the "Company"), a biotech innovator and biologics contract manufacturing organization, today announced its financial result
Read more →IBIOiBio Enters into Agreement with Safi Biosolutions to Develop Growth Factors and Cytokines Using the FastPharming System - Project Focused on Proteins used in the Production of Blood Cells - NEW YORK /
iBio Enters into Agreement with Safi Biosolutions to Develop Growth Factors and Cytokines Using the FastPharming System - Project Focused on Proteins used in the Production of Blood Cells - NEW YORK / October 2, 2020 / (GLOBE NEWSWIRE) / iBio, Inc. (NYSE AMERICAN:IBIO) ("iBi
Read more →IBIOGroup 1 Group 2 Group 3 Group 4 Group 5 Group 6 Group 7 0.0 0.2 0.4 0.6 0.8 1.0 A b s ( I g G 1 a n d I g G 2 c ) IgG1 IgG2c Group 24Group 25Group 26Group 27Group 28Group 29Group 30 0.0 0.5 1.0 1.5 2.0 A b s ( I g G 1 a
Group 1 Group 2 Group 3 Group 4 Group 5 Group 6 Group 7 0.0 0.2 0.4 0.6 0.8 1.0 A b s ( I g G 1 a n d I g G 2 c ) IgG1 IgG2c Group 24Group 25Group 26Group 27Group 28Group 29Group 30 0.0 0.5 1.0 1.5 2.0 A b s ( I g G 1 a n d I g G 2 c ) IgG1 IgG2c IBIO - 200 IBIO - 201 The Company
Read more →IBIOiBio Expands COVID-19 Vaccine Collaboration to Include the Infectious Disease Research Institute - The Nonprofit Will Help Lead Pre-Clinical Development and Clinical Trial Oversight - NEW YORK /
iBio Expands COVID-19 Vaccine Collaboration to Include the Infectious Disease Research Institute - The Nonprofit Will Help Lead Pre-Clinical Development and Clinical Trial Oversight - NEW YORK / April 9, 2020 / (GLOBE NEWSWIRE) / iBio, Inc. (NYSE AMERICAN:IBIO) ("iBio" or th
Read more →IBIOiBio Announces Advancement of COVID-19 Vaccine Program - Preclinical Immunization Studies at Texas A&M University - NEW YORK /
iBio Announces Advancement of COVID-19 - Preclinical Immunization Studies at Texas A&M University - NEW YORK / March 26, 2020 / (GLOBE NEWSWIRE) / iBio, Inc. (NYSE AMERICAN:IBIO) ("iBio" or the "Company"), a biologics contract manufacturing organization and biotechnology com
Read more →IBIOiBio Announces Development of Proprietary COVID-19 Vaccine Candidates - Several Provisional Patents Filed with USPTO - NEW YORK /
iBio Announces Development of Proprietary COVID-19 Vaccine Candidates - Several Provisional Patents Filed with NEW YORK / March 18, 2020 / (GLOBE NEWSWIRE) / iBio, Inc. (NYSE AMERICAN:IBIO) ("iBio" or the "Company"), a biologics contract manufacturing organization and biotec
Read more →IBIOIBIO, INC. ANNOUNCES POSTPONEMENT OF ANNUAL MEETING NEW YORK, NEW YORK, FEBRUARY 6, 2020 - IBIO, INC. (NYSE AMERICAN: IBIO) ("IBIO" OR THE "COMPANY") , today announced that the 2019 annual meeting of stockholders (the "A
IBIO, INC. ANNOUNCES POSTPONEMENT OF ANNUAL NEW YORK, NEW YORK, FEBRUARY 6, 2020 - IBIO, INC. (NYSE AMERICAN: IBIO) ("IBIO" OR THE "COMPANY"), today announced that the 2019 annual meeting of stockholders (the "Annual Meeting") originally scheduled to be held on Monday, Februa
Read more →IBIOIBIO, INC. ANNOUNCES NYSE AMERICAN ACCEPTANCE OF PLAN OF COMPLIANCE NEW YORK, NEW YORK, JANUARY 16, 2020 - IBIO, INC. (NYSE AMERICAN: IBIO) ("IBIO" OR THE "COMPANY") , today announced that it has received notice from NYS
IBIO, INC. ANNOUNCES NYSE AMERICAN ACCEPTANCE OF PLAN OF COMPLIANCE NEW YORK, NEW YORK, JANUARY 16, 2020 - IBIO, INC. (NYSE AMERICAN: IBIO) ("IBIO" OR THE "COMPANY"), today announced that it has received notice from NYSE American LLC (the "Exchange") that NYSE Regulation has
Read more →IBIOiBio, Inc. Reports on NYSE American Noncompliance Notice and Compliance Plan New York
iBio, Inc. Reports on NYSE American Noncompliance Notice New York, December 13, 2019 - iBio, Inc. (NYSE American: IBIO) ("iBio" or the "Company"), a leader in plant-based biologics manufacturing, announced today that on December 9, 2019, the Company received a letter from NYSE
Read more →IBIOIBIO, INC. PRICES $5,000,000 PUBLIC OFFERING NEW YORK, NEW YORK, OCTOBER 25, 2019 - IBIO, INC. (NYSE AMERICAN: IBIO) ("IBIO" OR THE "COMPANY") , today announced the pricing of an underwritten public offering with expecte
IBIO, INC. PRICES $5,000,000 PUBLIC OFFERING NEW YORK, NEW YORK, OCTOBER 25, 2019 - IBIO, INC. (NYSE AMERICAN: IBIO) ("IBIO" OR THE "COMPANY"), today announced the pricing of an underwritten public offering with expected total gross proceeds of approximately $5,000,000, before
Read more →IBIOIBIO, INC. REPORTS ON NYSE AMERICAN NONCOMPLIANCE NOTICE AND COMPLIANCE PLAN NEW YORK, NEW YORK, OCTOBER 22, 2019 - IBIO, INC. (NYSE AMERICAN: IBIO) ("IBIO" OR THE "COMPANY") announced today that on
IBIO, INC. REPORTS ON NYSE AMERICAN NONCOMPLIANCE NOTICE AND COMPLIANCE PLAN NEW YORK, NEW YORK, OCTOBER 22, 2019 - IBIO, INC. (NYSE AMERICAN: IBIO) ("IBIO" OR THE "COMPANY") announced today that on October 16, 2019, the Company received notice from NYSE American (the "Exchan
Read more →IBIOiBio Announces Appointment of Thomas F. Isett to Board of Directors Accomplished Life Science Executive with Deep Bioprocess Experience
iBio Announces Appointment of Thomas F. Isett to Board of Directors Accomplished Life Science Executive with Deep Bioprocess Experience NEW YORK, April 1, 2019 (GLOBE NEWSWIRE) - iBio, Inc. (NYSE AMERICAN:IBIO), a biologics contract manufacturer and product developer with pro
Read more →IBIOIBIO, INC. ANNOUNCES NYSE AMERICAN ACCEPTANCE OF PLAN OF COMPLIANCE NEW YORK, NEW YORK, AUGUST 22, 2018 - IBIO, INC. (NYSE AMERICAN: IBIO) ("IBIO" OR THE "COMPANY") , today announced that NYSE Regulation has accepted the
IBIO, INC. ANNOUNCES NYSE AMERICAN ACCEPTANCE OF PLAN OF COMPLIANCE NEW YORK, NEW YORK, AUGUST 22, 2018 - IBIO, INC. (NYSE AMERICAN: IBIO) ("IBIO" OR THE "COMPANY"), today announced that NYSE Regulation has accepted the Company's plan to regain compliance with the Exchange's
Read more →IBIOIBIO, INC. CLOSES $16,000,000 PUBLIC OFFERING NEW YORK, NEW YORK, JUNE 26, 2018 - IBIO, INC. (NYSE AMERICAN: IBIO) ("IBIO" OR THE "COMPANY") , today announced that it has closed its previously announced underwritten publ
IBIO, INC. CLOSES $16,000,000 PUBLIC OFFERING NEW YORK, NEW YORK, JUNE 26, 2018 - IBIO, INC. (NYSE AMERICAN: IBIO) ("IBIO" OR THE "COMPANY"), today announced that it has closed its previously announced underwritten public offering with expected total gross proceeds of approxim
Read more →IBIOIBIO, INC. PRICES $16,000,000 PUBLIC OFFERING NEW YORK, NEW YORK, JUNE 22, 2018 - IBIO, INC. (NYSE AMERICAN: IBIO) ("IBIO" OR THE "COMPANY") , today announced the pricing of an underwritten public offering with expected
IBIO, INC. PRICES $16,000,000 PUBLIC NEW YORK, NEW YORK, JUNE 22, 2018 - IBIO, INC. (NYSE AMERICAN: IBIO) ("IBIO" OR THE "COMPANY"), today announced the pricing of an underwritten public offering with expected total gross proceeds of approximately $16,000,000, before deducting
Read more →IBIOIBIO, INC. REPORTS ON NYSE AMERICAN NONCOMPLIANCE NOTICE AND COMPLIANCE PLAN NEW YORK, NEW YORK, JUNE 8, 2018 - IBIO, INC. (NYSE AMERICAN: IBIO) ("IBIO" OR THE "COMPANY") announced today that on
REPORTS ON NYSE AMERICAN NONCOMPLIANCE NOTICE AND COMPLIANCE PLAN NEW YORK, JUNE 8, 2018 - IBIO, INC. (NYSE AMERICAN: IBIO) ("IBIO" OR THE "COMPANY") announced today that on June 6, 2018, the Company received a letter from NYSE American LLC ("NYSE American" or the "Exchange")
Read more →IBIOIBIO, INC. ANNOUNCES REVERSE STOCK SPLIT NEW YORK, NEW YORK, MAY 31, 2018 - IBIO, INC. (NYSE AMERICAN: IBIO) ("IBIO" OR THE "COMPANY") announced today a reverse split of its Common Stock, par value $0.001 per share (the
IBIO, INC. ANNOUNCES REVERSE STOCK SPLIT NEW YORK, NEW YORK, MAY 31, 2018 - IBIO, INC. (NYSE AMERICAN: IBIO) ("IBIO" OR THE "COMPANY") announced today a reverse split of its Common Stock, par value $0.001 per share (the "Common Stock"), at a ratio of 1 for 10, effective on Jun
Read more →IBIOIBIO, INC. PROVIDES CORPORATE UPDATE NEW YORK, NEW YORK, JANUARY 5, 2018 - IBIO, INC. (NYSE AMERICAN: IBIO) ("IBIO" OR THE "COMPANY") announced today its receipt of notice that Staff of NYSE American LLC determined that
IBIO, INC. PROVIDES CORPORATE UPDATE NEW YORK, NEW YORK, JANUARY 5, 2018 - IBIO, INC. (NYSE AMERICAN: IBIO) ("IBIO" OR THE "COMPANY") announced today its receipt of notice that Staff of NYSE American LLC determined that the Company's securities ". . . have been selling for a l
Read more →IBIOIBIO, INC. CLOSES $4,500,000 OFFERING OF COMMON STOCK NEW YORK, NEW YORK, NOVEMBER 30, 2017 - IBIO, INC. (NYSE AMERICAN: IBIO) ("IBIO" OR THE "COMPANY") , today announced the closing of its previously announced public of
IBIO, INC. CLOSES $4,500,000 OFFERING NEW YORK, NEW YORK, NOVEMBER 30, 2017 - IBIO, INC. (NYSE AMERICAN: IBIO) ("IBIO" OR THE "COMPANY"), today announced the closing of its previously announced public offering of 22,500,000 shares of its common stock at a price to the public o
Read more →IBIOIBIO, INC. PRICES $4,500,000 FIRM COMMITMENT OFFERING OF COMMON STOCK NEW YORK, NEW YORK, NOVEMBER 29, 2017 - IBIO, INC. (NYSE AMERICAN: IBIO) ("IBIO" OR THE "COMPANY"), today announced the pricing of a firm commitment p
$4,500,000 FIRM COMMITMENT OFFERING OF COMMON STOCK NEW YORK, NEW YORK, NOVEMBER 29, 2017 - IBIO, INC. (NYSE AMERICAN: IBIO) ("IBIO" OR THE "COMPANY"), today announced the pricing of a firm commitment public offering of 22,500,000 shares of its common stock at a price to the p
Read more →IBIOiBio, Inc. Initiates Litigation Against Fraunhofer-Gesellschaft in Delaware Chancery Court New York, NY--(
iBio, Inc. Initiates Litigation Against Fraunhofer-Gesellschaft in Delaware Chancery Court New York, NY--(November 6, 2017) - iBio, Inc. (NYSE AMERICAN: IBIO), a leading provider of plant-based biotechnology for developing and manufacturing biological products, announced toda
Read more →IBIOiBio, Inc. Enters into Common Stock Purchase Agreement for Up to $16.0 Million with Lincoln Park Capital Receives Initial Investment of $1.0 Million New York, NY
iBio, Inc. Enters into Common Stock Purchase Agreement for Up to $16.0 Million with Lincoln Park Capital Receives Initial Investment of $1.0 Million New York, NY, July 24, 2017- iBio, Inc. (NYSE MKT: IBIO) ("iBio"), a leader in developing plant-based biopharmaceuticals, anno
Read more →IBIOiBio, Inc. Holds Annual Meeting in College Station, Texas NEW YORK, NY--(Marketwired
Annual Meeting in College Station, Texas NEW YORK, NY--(Marketwired - Apr 7, 2016) - iBio, Inc. (NYSE MKT: IBIO) - Speaking to shareholders at the iBio, Inc. (NYSE MKT: IBIO) Annual Meeting today, Chairman and Chief Executive Officer Robert B. Kay highlighted the Company's mos
Read more →IBIOiBio Forms Joint Venture CMO for Large-Scale Pharmaceuticals Manufacturing in Green Plants and Accepts Additional Investment NEW YORK, NY. (
iBio Forms Joint Venture CMO for Large-Scale Pharmaceuticals Manufacturing in Green Plants and Accepts Additional Investment NEW YORK, NY. (January 14, 2016) - iBio, Inc. (NYSE MKT: IBIO), a leader in plant-based biotechnology for developing and manufacturing biological produc
Read more →IBIOiBio Enters Into $10 Million Common
iBio Enters Into $10 Million Common Purchase Agreement with Aspire Capital NEWARK, DE August 26, 2014 - iBio, Inc. (NYSE MKT: IBIO), a leading provider of plant-based biotechnology for developing and manufacturing biological products, today announced it has entered into a com
Read more →IBIOiBio, Inc. Receives Notice that NYSE MKT Accepted the Company's Plan to Regain Compliance with Continued Listing Standards NEWARK, DEL.
iBio, Inc. Receives Notice that NYSE MKT Accepted the Company's Plan to Regain Compliance with Continued Listing Standards NEWARK, DEL., June 5, 2013 /PRNewswire/ - iBio, Inc. (NYSE MKT: IBIO) today announced that on May 31, 2013, the NYSE MKT (the "Exchange") notified the Com
Read more →IBIOiBio, Inc. Announces Proposed Public Offering Newark, Del.
iBio, Inc. Announces Proposed Public Offering Newark, Del., April 22, 2013 /PRNewswire/ iBio, Inc. (NYSE MKT: IBIO) today announced that it is offering shares of its common stock and common stock purchase warrants in an underwritten public offering. The offering is subject to
Read more →IBIOiBio, Inc. receives Notice from NYSE MKT Staff that Company currently is not in compliance with an additional Continued Listing Standard Newark, Del.
iBio, Inc. receives Notice from NYSE MKT Staff that Company currently is not in compliance with an additional Continued Listing Standard Newark, Del., April 22, 2013 - iBio, Inc. (NYSE MKT: IBIO) announced today that the Company has received notice from NYSE MKT (the "Exchange
Read more →IBIOiBio, Inc. Receives Anticipated Notice from NYSE MKT that Company is Below Certain Continued Listing Standards. NEWARK, DEL.
iBio, Inc. Receives Anticipated Notice from NYSE MKT that Company is Below Certain Continued Listing Standards. NEWARK, DEL., March 4, 2013 - PRNewswire - iBio, Inc. (NYSE MKT: IBIO) today announced that it has been notified by the NYSE MKT (the "Exchange") Staff that the Comp
Read more →IBIOiBio Announces At-the-Market Equity Offering
iBio Announces At-the-Market Equity Offering NEWARK, Del., February 1, 2013 /PRNewswire/ -- iBio, Inc. (NYSE MKT: IBIO) entered into an "At-the-Market" (ATM) equity offering sales agreement with the Donjon Group, a division of Further Lane Securities, L.P. on January 31, 2013,
Read more →IBIOiBio, Inc. Receives Notice from NYSE MKT Staff that Company Currently is Below Certain Continued Listing Standards
iBio, Inc. Receives Notice from NYSE MKT Staff that Company Currently is Below Certain Continued Listing Standards NEWARK, Del., Nov. 23, 2012 iBio, Inc. (NYSE MKT: IBIO) announced that the Company today received notice from NYSE MKT (the Exchange ) Staff that the Company curr
Read more →IBIOiBio, Inc. Announces Proposed Public Offering
iBio, Inc. Announces Proposed Public Offering Jan. 9, 2012 /PRNewswire/ - iBio, Inc. (NYSE AMEX: IBIO) today announced that it intends to offer shares of its common stock and common stock purchase warrants in an underwritten public offering. Roth Capital Partners, LLC is acting
Read more →IBIOiBio, Inc. Receives Notice from NYSE Amex Staff that Company Currently is Below Certain Continued Listing Standards
iBio, Inc. Receives Notice from NYSE Amex Staff that Company Currently is Below Certain Continued Listing Standards NEWARK, Del., Nov. 4, 2011 iBio, Inc. (NYSE AMEX: IBIO) announced that the Company today received notice from NYSE Amex (the "Exchange") Staff that the Company cur
Read more →IBIOJules A. M sing Joins iBio's Board of Directors NEWARK, Del.--(BUSINESS WIRE)-- iBio, Inc. (NYSE AMEX: IBIO) announced today the appointment of Jules A. M sing, formerly a senior executive at Johnson & Johnson, to iBio's
Jules A. M sing Joins iBio's Board of Directors NEWARK, Del.--(BUSINESS WIRE)-- iBio, Inc. (NYSE AMEX: IBIO) announced today the appointment of Jules A. M sing, formerly a senior executive at Johnson & Johnson, to iBio's In the course of his career at Johnson & Johnson, Mr. M
Read more →IBIOiBio Appoints Douglas Beck Chief Financial Officer NEWARK, Del.--(BUSINESS WIRE)-- iBio, Inc. (NYSE AMEX:IBIO) announced today that Douglas Beck, C.P.A. has joined the company as Chief Financial Officer. Mr. Beck has ext
iBio Appoints Douglas Beck Chief Financial Officer NEWARK, Del.--(BUSINESS WIRE)-- iBio, Inc. (NYSE AMEX:IBIO) announced today that Douglas Beck, C.P.A. has joined the company as Chief Financial Officer. Mr. Beck has extensive prior experience in public accounting including a
Read more →IBIOGame-Changing Technology for the Vaccine and Therapeutic Biologics Business Noble Financial Sixth Annual Equity Conference ONTRACK 2010 This presentation may contain forward-looking statements within the meaning of the P
Game-Changing Technology for the Vaccine and Therapeutic Biologics Business Noble Financial Sixth Annual Equity Conference This presentation may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are
Read more →IBIOiBio, Inc. Announces Agreement in Principle for Licensing Large-Scale Vaccine Production Facility Using Green Plant Technology
iBio, Inc. Announces Agreement in Principle for Licensing Large-Scale Vaccine Production Facility Using Green Plant Technology NEWARK, Del., Feb 26, 2010 (BUSINESS WIRE) -- iBio, Inc. (IBPM) announced today that it has agreed in principle to license its technology, the iBioLaunc
Read more →IBIORobert Erwin Melody Carey President Co-President iBio, Inc. Rx Communications, Inc. 302-355-2335 917-322-2571 rerwin@ibioinc.com mcarey@rxir.com FOR IMMEDIATE RELEASE iBio Com pletes $3 Million Private Placement
Robert Erwin Melody Carey President Co-President iBio, Inc. Rx Communications, Inc. 302-355-2335 917-322-2571 rerwin@ibioinc.com mcarey@rxir.com iBio Completes $3 Million Private Placement NEWARK, DE - September 10, 2009 - iBio, Inc. (OTCBB: IBPM) today announced a private
Read more →IBIOdemand, and the Company's ability to obtain new contracts and accurately estimate net revenues due to variability in size, scope and duration of projects.
NEWS RELEASE for August 20, 2008 Contact: Dina Masi, Interim CFO Jeffrey Leach, Investor Relations j.leach@ibiopharma.com IBIOPHARMA, INC. ANNOUNCES THE COMPLETION OF $5.0 MILLION PRIVATE PLACEMENT NEWARK, DE, August 20, 2008 -- iBioPharma, Inc. (OTCBB:IBPM) (the "Company")
Read more →Competitive Position
How IBIO ranks across every disease it competes inCompetitive Position is a premium feature
See how IBIO ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial